Replies to post #34745 on *** MICK, $Pistol Pete$ & FRIENDS STOCK PICKS

[$Pistol Pete$]

$PLUG 3 Months Chart

[$Pistol Pete$]

$LVGI SLAM Haymaker on YouTube LVGI

Go $LVGI

[$Pistol Pete$]

$MNKD FLYNN JAMES E PICKED MANNKIND CORP (NASDAQ:MNKD) SHARES MNKD



In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Mannkind Corp (NASDAQ:MNKD) reported that Flynn James E has picked up 5,217,391 of common stock as of 2017-04-19.

The acquisition brings the aggregate amount owned by Flynn James E to a total of 5,217,391 representing a 5.17% stake in the company.

For those not familiar with the company, MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company’s fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

A glance at Mannkind Corp (NASDAQ:MNKD)’s key stats reveals a current market capitalization of 113.14 Million based on 95.78 Million shares outstanding and a price at last close of $1.22 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-01-03, Pfeffer picked up 4,540 at a purchase price of $0.54. This brings their total holding to 403,085 as of the date of the filing.

On the sell side, the most recent transaction saw Alinaya unload 6,294 shares at a sale price of $1.06. This brings their total holding to 131,413.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Mannkind Corp (NASDAQ:MNKD) as things move forward to see if its progress aligns with these transactions.

[$Pistol Pete$]

$CLDR will be a good long term hold

[$Pistol Pete$]

Good morning MICK

[$Pistol Pete$]

$PNTV http://www.otcmarkets.com/stock/PNTV/news/Player-s-Network-Subsidiary-Awarded-Medical-Marijuana-Licenses?id=160466

[$Pistol Pete$]

$MACK Taking a Look at the Data Behind Merrimack Pharmaceuticals, Inc. (MACK)

https://stocknewsjournal.com/2017/05/30/taking-a-look-at-the-data-behind-merrimack-pharmaceuticals-inc-mack/
Taking a Look at the Data Behind Merrimack Pharmaceuticals, Inc. (MACK)

StockNewsJournal - 11h ago


Merrimack Pharmaceuticals, Inc. (MACK) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $3.30, down from yesterday's close by -2.94%.

[MarketProphet]

Here's one for you $LAGBF this company is currently doing nearly $1.7 Million a Month already with their sales. CBD and THC Product line. Here's their website https://isodiol.com/

Also they are in New York as we speak sponsoring this event, this a company that you should put on the watch list. LAGBF


Isodiol International takes major sponsorship role at the NY Cannabis World Congress & Business Expo
LAGBF, C.ISOL, ISOL | 17 hours ago

Canada NewsWire
VANCOUVER, June 14, 2017
VANCOUVER, June 14, 2017 /CNW/ - Isodiol International Inc.- (CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the "Company" or "Isodiol") a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce we are one of the key sponsors at the NY Cannabis World Congress & Business Expo this June 14-16.
This annual cannabis business event is held at the Jacob K. Javits Convention Center in NY and is the leading forum for doing business in one of the fastest growing industries in the United States. 
"Isodiol is also honored to have Dr. Ron Aung-Din, a neurologist with over 35 years of experience in General Neurology and Neuro-Psychiatry, speaking about the positive benefits and advancements of phytocannabinoids and presenting IsoDerm, a premium product he developed along with the team at Isodiol," said Isodiol's CEO Marcos Agramont.
"Sponsoring this event along with having Dr. Ron Aung-Din present at the seminar, gives Isodiol key exposer to play an active roll in our industry and meet with global vendors and investors to speak firsthand with them about what we believe, which is, we are at the start of significant global operational highlights that will give our company a very strong foundation for customer engagement and retention, while accelerating Isodiol's pace of innovation and competitive differentiation moving forward, with our brands like CBD Naturals, Iso-Sport, CannaCeuticals CBD Skincream, and Pot-O-Coffee," said Agramont. 
About Isodiol International Inc.
Isodiol International, Inc. is the market leader in pharmaceutical grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for Hemp-derived cannabidiol (CBD), including 99% pure crystalline isolate, micro-encapsulation, and nano technology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries and will aggressively continue International expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
"Marcos Agramont"
CEO & Director

Read more at http://www.stockhouse.com/news/press-releases/2017/06/14/isodiol-international-takes-major-sponsorship-role-at-the-ny-cannabis-world#H07TH7UIGMQkQFOW.99

[MarketProphet]

Here's one for you $LAGBF this company is currently doing nearly $1.7 Million a Month already with their sales. CBD and THC Product line. Here's their website https://isodiol.com/

Also they are in New York as we speak sponsoring this event, this a company that you should put on the watch list. LAGBF


Isodiol International takes major sponsorship role at the NY Cannabis World Congress & Business Expo
LAGBF, C.ISOL, ISOL | 17 hours ago

Canada NewsWire
VANCOUVER, June 14, 2017
VANCOUVER, June 14, 2017 /CNW/ - Isodiol International Inc.- (CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the "Company" or "Isodiol") a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce we are one of the key sponsors at the NY Cannabis World Congress & Business Expo this June 14-16.
This annual cannabis business event is held at the Jacob K. Javits Convention Center in NY and is the leading forum for doing business in one of the fastest growing industries in the United States. 
"Isodiol is also honored to have Dr. Ron Aung-Din, a neurologist with over 35 years of experience in General Neurology and Neuro-Psychiatry, speaking about the positive benefits and advancements of phytocannabinoids and presenting IsoDerm, a premium product he developed along with the team at Isodiol," said Isodiol's CEO Marcos Agramont.
"Sponsoring this event along with having Dr. Ron Aung-Din present at the seminar, gives Isodiol key exposer to play an active roll in our industry and meet with global vendors and investors to speak firsthand with them about what we believe, which is, we are at the start of significant global operational highlights that will give our company a very strong foundation for customer engagement and retention, while accelerating Isodiol's pace of innovation and competitive differentiation moving forward, with our brands like CBD Naturals, Iso-Sport, CannaCeuticals CBD Skincream, and Pot-O-Coffee," said Agramont. 
About Isodiol International Inc.
Isodiol International, Inc. is the market leader in pharmaceutical grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for Hemp-derived cannabidiol (CBD), including 99% pure crystalline isolate, micro-encapsulation, and nano technology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries and will aggressively continue International expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
"Marcos Agramont"
CEO & Director

Read more at http://www.stockhouse.com/news/press-releases/2017/06/14/isodiol-international-takes-major-sponsorship-role-at-the-ny-cannabis-world#H07TH7UIGMQkQFOW.99

[$Pistol Pete$]

$PMCB Daily and Weekly Charts

[$Pistol Pete$]

Good morning MICK

[$Pistol Pete$]

$RAD https://www.baseball-news-blog.com/2017/07/18/rite-aid-corporation-rad-bonds-trading-2-7-higher-updated.html
Rite Aid Corporation (NYSE:RAD) Bonds Rise 2.7% During Trading
BNB Daily (blog) - 2h ago


Rite Aid Corporation logo An issue of Rite Aid Corporation (NYSE:RAD) bonds rose 2.7% against their face value during trading on Monday.

[$Pistol Pete$]

$LVGI Limitless Venture Group Inc (LVGI) Seeing Increased Action in Session LVGI

Shares of Limitless Venture Group Inc (LVGI) is moving on volatility today 33.33% or 0.0001 from the open. The OTC listed company saw a recent bid of 0.0004 on 13230000 volume.

Investors may be searching high and low for the next breakout winner in the stock market. As companies continue to release quarterly earnings reports, investors will be looking for stocks that have the potential to move to the upside in the coming months. Tracking earnings can be a good way for investors to see how the company is stacking up to analyst estimates. Some investors prefer to track sell-side estimates very closely. Others prefer to do their own research and make their own best guesses on what the actual numbers will be. A solid earnings beat may help ease investor worries if the stock has been underperforming recently. On the flip side, a bad earnings miss may cause investors to take a much closer look at what the future prospects look like for the company.

Digging deeping into the Limitless Venture Group Inc (LVGI) ‘s technical indicators, we note that the Williams Percent Range or 14 day Williams %R currently sits at 0.00. The Williams %R oscillates in a range from 0 to -100. A reading between 0 and -20 would point to an overbought situation. A reading from -80 to -100 would signal an oversold situation. The Williams %R was developed by Larry Williams. This is a momentum indicator that is the inverse of the Fast Stochastic Oscillator.

Limitless Venture Group Inc (LVGI) currently has a 14-day Commodity Channel Index (CCI) of 270.18. Active investors may choose to use this technical indicator as a stock evaluation tool. Used as a coincident indicator, the CCI reading above +100 would reflect strong price action which may signal an uptrend. On the flip side, a reading below -100 may signal a downtrend reflecting weak price action. Using the CCI as a leading indicator, technical analysts may use a +100 reading as an overbought signal and a -100 reading as an oversold indicator, suggesting a trend reversal.

Currently, the 14-day ADX for Limitless Venture Group Inc (LVGI) is sitting at 22.47. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would support a strong trend. A value of 50-75 would identify a very strong trend, and a value of 75-100 would lead to an extremely strong trend. ADX is used to gauge trend strength but not trend direction. Traders often add the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) to identify the direction of a trend.

The RSI, or Relative Strength Index, is a widely used technical momentum indicator that compares price movement over time. The RSI was created by J. Welles Wilder who was striving to measure whether or not a stock was overbought or oversold. The RSI may be useful for spotting abnormal price activity and volatility. The RSI oscillates on a scale from 0 to 100. The normal reading of a stock will fall in the range of 30 to 70. A reading over 70 would indicate that the stock is overbought, and possibly overvalued. A reading under 30 may indicate that the stock is oversold, and possibly undervalued. After a recent check, the 14-day RSI for Limitless Venture Group Inc is currently at 61.74, the 7-day stands at 71.34, and the 3-day is sitting at 86.64.

https://evergreencaller.com/limitless-venture-group-inc-lvgi-seeing-increased-action-in-session/

[$Pistol Pete$]

$MFST Medifirst Appoints Executive Advisor for China MFST

https://finance.yahoo.com/news/medifirst-appoints-executive-advisor-china-154611088.html

[Angel010910]

SLDC .036 NEWEST MARIJUANA STOCK WHICH IS UNKNOWN. THIS CAN RUN OVER $1 WHEN THE CROWD FINDS OUT SLDC HAS THE TINIEST FLOAT OF ALL MMJ STOCKS IN THE COUNTRY BY FAR!!!!! 350 MILLION A\S? HEMP HAS 5.5 BILLION A\S AND AT THE SAME PRICE!!

[$Pistol Pete$]

$UNGS https://www.sec.gov/Archives/edgar/data/1695473/000147793217003439/gcc_s1a.htm#PROSPECTUS%20SUMMARY

[$Pistol Pete$]

$MFST Medifirst Appoints Executive Advisor for China MFST

https://finance.yahoo.com/news/medifirst-appoints-executive-advisor-china-154611088.html

[$Pistol Pete$]

Good afternoon Mick

[$Pistol Pete$]

$MFST Medifirst Signs Distribution Agreement for Morocco MFST





FREEHOLD, NJ--(Marketwired - Aug 31, 2017) - MEDIFIRST SOLUTIONS, INC. ( OTC PINK : MFST ) (the "Company" or "Medifirst"), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, is pleased to announce that it has signed a distribution agreement with an international distribution company based in Morocco. The three-year term of this Agreement grants the distributor exclusivity for the country of Morocco so long as the distributor meets aggregate sales of $375,000 USD.

Commented Medifirst's President, Bruce Schoengood, "Our first international presentation was in Morocco and we are very excited and pleased to be entering this market. We continue to see a demand for new, non-addictive, natural and effective ways to treat people suffering from acute and chronic pain. We are working with our distribution partner in Morocco to complete the device registration process, which we believe is almost complete, and we are confident we will be successful." No assurances can be made that the Company will be granted clearance to sell or, if clearance is achieved, that the distributor will be successful in its sales efforts.

Medifirst recently announced a distribution arrangement for Mid-East territories, including Lebanon, Kuwait, Saudi Arabia, United Arab Emirates, Bahrain, Qatar, Oman, Jordan and Iraq. The Company is currently training and working with the distributors and their representatives as part of the introduction and roll-out process. Medifirst continues to receive strong interest for its product in China and, though no assurances can be made, it anticipates providing updates on the progress of these discussions in the upcoming days and weeks. The Company is working diligently to tackle the US market and it has added a number of consultants and sales representatives in the recent weeks. Additionally, Medifirst continues to offer the Time Machine Infrared Laser as part of its aggressive 30 day free trial, no strings attached program. The Company also anticipates further updates on its US market efforts in the upcoming days and weeks.

About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for "The Time Machine" Series Laser, received clearance from the U.S. Food and Drug Administration ("FDA") to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.

Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

[$Pistol Pete$]

$PMCB PharmaCyte Biotech Appoints Dr. Linda S. Sher as Chief Medical Officer PMCB


LAGUNA HILLS, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the appointment of Linda S. Sher, M.D. as the company’s Chief Medical Officer.

Dr. Sher is a Professor of Clinical Surgery and Director of Clinical Research in the Division of Hepatobiliary and Pancreatic Surgery and Abdominal Organ Transplantation at the University of Southern California’s (USC) Keck School of Medicine. Dr. Sher is also the Chief of the Division of Clinical Research for the Department of Surgery where she oversees the implementation and conduct of clinical trials for the entire department, averaging between 50 and 70 studies at all times. She is also the Vice Chair of the USC Institutional Review Board.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are extremely fortunate to have someone with Dr. Sher’s credentials and experience in such a critically important position as our Chief Medical Officer. Dr. Sher will be responsible for the strategy, direction and execution of PharmaCyte’s clinical development plans, an essential position for a biotech company about to embark upon a pivotal trial in pancreatic cancer.

“Not only will Dr. Sher be a key member of the senior management team, she will oversee our entire clinical research program. Dr. Sher has been the Principal or Co-Principal Investigator on more than 50 clinical trials. This experience is invaluable to PharmaCyte. Dr. Sher is expected to contribute considerably to our success as a biotech company and, most importantly, to a successful pivotal trial in pancreatic cancer.”

Commenting on her appointment, Dr. Sher said, “I am joining PharmaCyte at a major inflection point in the company’s evolution as a biotech company with potentially game-changing technology in the way solid tumors are treated. This is an exciting time for PharmaCyte, and I am pleased that I have been asked to play such a major and important role in the company.”

Dr. Sher will oversee the structure, conduct and reporting of PharmaCyte’s clinical trials and will represent PharmaCyte in its interactions with the company’s clinical trial investigators, regulatory agencies, key opinion leaders, the investment, medical and regulatory communities, as well as pharmaceutical and biotechnology sector collaborators and potential partners.

After completing her medical school education and surgical residency at Mount Sinai School of Medicine in New York, Dr. Sher had fellowship training at the University of Pittsburgh in Liver and Kidney Transplantation under the tutelage of Dr. Thomas Starzl. Dr. Starzl was a renowned physician, researcher and expert on organ transplants. He performed the first liver transplant and is often referred to as “the father of modern transplantation.” Following completion of her fellowship program in 1988, Dr. Sher was involved in the establishment of two liver transplant programs in Los Angeles before joining the USC program in 2001.

Dr. Sher has participated in the surgery and management of patients with end stage liver disease, hepatobiliary and pancreatic disease and liver transplant recipients for more than 30 years. She has used her experience as Principal or Co-Principal Investigator for more than 50 clinical trials and as an opportunity to mentor young faculty at USC in the conduct of clinical trials. Dr. Sher is active in the clinical and basic science research components of the Abdominal Organ Transplantation Program at USC. She has authored or co-authored articles on immunosuppression, chronic rejection, disease recurrence, infection, hepatobiliary surgery and transplant outcomes. Dr. Sher is one of the original editors of Current Opinion in Organ Transplantation, which provides the reader with an up to date overview of the entire field of organ transplantation.

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. Kenneth L. Waggoner is the Chief Executive Officer, President, General Counsel and Chairman of the Board.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through the encapsulated cells, they act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.

Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: [phone]
Email: [e-mail]

https://globenewswire.com/news-release/2017/07/26/1062849/0/en/PharmaCyte-Biotech-Appoints-Dr-Linda-S-Sher-as-Chief-Medical-Officer.html

[$Pistol Pete$]

$EQLB EQ Labs, Inc. (EQLB) Investors' Update EQLB

EQ Labs, Inc. (EQLB) Investors Update

Las Vegas, NV -- August 30, 2017 -- InvestorsHub NewsWire -- Mo Owens, CEO EQ Labs Inc. (EQLB) is proud to announce a major equity ownership position in Las Vegas based AirGo Food & Beverage (AF&B). The additional focus for distribution of their flagship beverage, Last Shot includes moving beyond the Las Vegas base of customers and into the government and corporate food & beverage merchandising and distribution arena. EQLB/AF&B as a Service Disabled Veteran Owned Business (SDVOSB) has initiated a market penetration campaign, using the VAs Veterans First Program, to gain access to Patriot Stores, operated by the VAs Canteen Services (VCS) where they operate over 200 Patriot Stores in Veterans Administration (VA) Medical Centers nationwide.

In addition, we will also target the giant commissary stores network located on military bases across the United States and elsewhere, says EQLBs Ron Washington who is an equity owner and a U.S. Marine Corps Vietnam combat veteran who is 100% disabled. These stores have been recently updated and expanded to provide customers with a modern, clean and comfortable shopping experience.

The other target, The Defense Commissary Agency (DeCA), headquartered at Fort Lee (Virginia), is the agency of the United States Department of Defense (DoD) that operates more than 245 commissaries worldwide. American military commissaries sell groceries and household goods to active-duty, Guard, Reserve, and retired members of all seven uniformed services of the United States and eligible members of their families.

Last Shot is a natural beverage choice for the health and fitness conscious military service person and their families. Says Washington. He goes on to state, I shop at the Patriot Stores, as do many other veterans every time I visit a VA facility and as a disabled veteran business owner I am eager to have the VA and other government agencies buy my products.

In addition, EQLB Distribution has initiated contacts with and generated a great deal of interest among many well-known corporate retail giants who focus on warehouse and bulk sales as well as to the major distributors to the nations top airport retailers, to casinos and resort hotels both in Las Vegas and beyond. These marketing efforts have allowed them to participate in serious developmental meetings with these major leaders in the retail food & beverage industry.

This is the exciting part, says Washington, when a small business attracts the attention of world-class food & beverage leaders and then after all of that hard work something happens. #

For further information contact Norvel McDonald, Sr. VP Marketing, AirGo F&B. [e-mail]

Safe Harbor:

This news release contains forward-looking statements as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. These forward-looking statements generally can be identified by phrases such as EQ Labs, Inc. or its management believes, expects, anticipates, foresees, forecasts, estimates or other words or phrases of similar import. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new business opportunities and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report, our quarterly reports and other periodic reports filed from time-to-time with the OTC Markets.

Contact Information: EQ Labs, Inc. CEO Phone: [phone]

Web: www.Drinklastshotlv..com - Email: [e-mail]

[$Pistol Pete$]

$PMCB PharmaCyte Restructures Agreements with Austrianova to Strengthen Partnership PMCB




LAGUNA HILLS, CA, September 6, 2017 (BUSINESS WIRE) -- PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has reached an agreement with Austrianova to restructure certain agreements between them pursuant to a Binding Term Sheet (Term Sheet).

The Term Sheet provides that PharmaCyte’s obligation to make milestone payments under the Asset Purchase Agreement, the Diabetes Licensing Agreement and the Cannabis Licensing Agreement are eliminated in their entirety. Also, the royalty fees and sublicensing royalty fees are reduced in the two licensing agreements. The Term Sheet further amends the Diabetes Licensing Agreement by expanding the scope of the licensed rights to cover encapsulation of all cell types and cells lines of any kind now in existence or later identified, including stem cells at all stages of differentiation and from any source specifically designed to produce insulin for the treatment of diabetes.

The Term Sheet also provides PharmaCyte with a 5-year right of first refusal in the event Austrianova chooses to sell, assign or transfer the Cell-in-a-Box® tradename and its associated technology, intellectual property, trade secrets and “know-how” (Associated Technologies). This includes the right to purchase any manufacturing facility used with the Cell-in-a-Box® process, as well as a non-exclusive license for the special cellulose sulphate utilized in that process. Additionally, for a period of one year from the date of the Term Sheet, Austrianova has agreed not to solicit, negotiate or entertain any inquiry regarding the potential acquisition of Cell-in-a-Box® and its Associated Technologies.

PharmaCyte has agreed to share with Austrianova 50% of any financial and non-financial consideration it receives from sublicenses under the Asset Purchase Agreement, the Diabetes Licensing Agreement and the Cannabis Licensing Agreement. PharmaCyte has also agreed to pay Austrianova $150,000 per month for the next 6 months. Prof. Walter H. Günzburg, Chairman of the Board of Austrianova, who currently serves as PharmaCyte’s Chief Scientific Officer, has agreed to continue his work for PharmaCyte without cash compensation for the same period.

Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, commented on the restructuring saying, “We have worked diligently with Austrianova to find ways that better align our interests as partners to achieve PharmaCyte’s goals. The provisions of the Term Sheet do just that. Not only has Austrianova made significant financial concessions, Austrianova has agreed to provide us with a vehicle by which we can acquire Cell-in-a-Box® and its Associated Technologies, including the manufacturing facility that will encapsulate the live cells required for our pancreatic cancer therapy and the other therapies we are developing that utilize the Cell-in-a-Box® technology.

“We felt that securing the right of first refusal now was imperative, as we move forward with our planned clinical trial in locally advanced pancreatic cancer. We also believe that these changes will serve to strengthen the partnership that has existed between PharmaCyte and Austrianova since we initially acquired the right to use this remarkable technology.”

Prof. Gunzburg, the Chairman of Austrianova, said, “The next 6 months will be an exciting time in the further alignment of our respective companies. PharmaCyte has always been an important partner for Austrianova, and we are looking forward to intensifying our mutually beneficial relationship.”

The Term Sheet memorializes the agreement between the parties to amend their principal agreements. Those amendments are in the process of being drafted and should be finalized and signed by the parties in the near term.

[$Pistol Pete$]

$ISBG http://www.nasdaq.com/press-release/isbg-announces-corporate-actions-name-change-20170907-01315
ISBG Announces Corporate Actions, Name Change
Nasdaq - 41m ago


LAS VEGAS, Sept. 07, 2017 (GLOBE NEWSWIRE) -- International Spirit and Beverage Group Inc., (a Nevada Corporation) (OTCPK:ISBG) is excited to announce that the company has legally completed a series of corporate actions.

[beambe]

CRMD-$$$

[mick]

$VNDM


*SINX-10M bidder .0015 being hidden.
interesting $sinx

UNVC has some chatter - what do you think?

i will read $$UNVC

[$Pistol Pete$]

$MNKD FDA Determines that Afrezza REMS Communication Plan Has Met Goals and REMS No Longer Necessary

Source: GlobeNewswire Inc.

MannKind Corporation (Nasdaq:MNKD), focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced that the Food and Drug Administration (FDA) has completed its review of a supplemental New Drug Application (sNDA) for Afrezza (insulin human) inhalation powder and has determined that the Risk Evaluation and Mitigation Strategy (REMS) communication plan regarding the risks of Afrezza has been completed and has met its goals. As a result, the FDA has decided that a REMS is no longer required for Afrezza.
“We are pleased that the FDA determined that a communication plan is no longer necessary to ensure the benefits of Afrezza outweigh its risks and that a REMS is no longer required,” stated Dr. David Kendall, Chief Medical Officer of MannKind. “We are grateful for the FDA’s guidance and expediency in this process, and we look forward to advancing our goal of establishing inhaled insulin as a preferred treatment option for individuals with diabetes who require mealtime glucose control.”

The FDA approved the original REMS for Afrezza in June 2014, and a REMS modification took effect in April 2015. The REMS consisted of a communication plan intended to inform prescribers of Afrezza of the potential risks associated with the use of Afrezza as described in the boxed warning. Two subsequent REMS assessments were conducted following Afrezza’s approval, and both assessments found that the communication plan met its goals.

The release of the REMS means that no further assessments are necessary; had it not been released, additional assessments would have been conducted at seven years post-approval. The Afrezza website, www.afrezzarems.com, will be inactivated, and the Company will no longer be required to distribute the Afrezza fact sheet at scientific meetings.

About Afrezza®
Available by prescription, Afrezza® (insulin human) inhalation powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within about 12 minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information on Afrezza, please visit www.afrezza.com.

About MannKind
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) inhalation powder, the Company's first FDA approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in MannKind's filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2017. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

MannKind Contact:
Rose Alinaya
SVP, Investor Relations
818-661-5000
[e-mail]



Primary Logo

[insymbols]

$BRGO annual report

https://ih.advfn.com/p.php?pid=nmona&article=77252410

[$Pistol Pete$]

F.A.M.I.L.Y
is one of the sweetest word
Anyone can say,
Because
The letters of FAMILY means…
“Father and Mother I Love You.. !!”

Happy Father’s Day Everyone

[$Pistol Pete$]

$PMCB Daily and Weekly Chart

[$Pistol Pete$]

$RAD Daily and Weekly Chart

[$Pistol Pete$]

$MU this is a big joke from China

Micron to Challenge Chinese Court Ruling Over Alleged Patent Infringement

Source: Dow Jones News
By Austen Hufford
Micron Technology Inc., America's largest memory-chip maker, is challenging a Chinese court decision that temporarily halted the sale of some of its products in the country.

Micron said Thursday that a Chinese court in the Fujian Province temporarily stopped the sale of certain Crucial and Ballistix-branded memory modules and solid state drives, which make up slightly more than 1% of the company's total annual revenue.

Micron said it would comply with the ruling while also asking the court to reconsider or stay its decision. The company expects its revenue for the current quarter to be within its previously guided range of $8 billion to $8.4 billion.

Shares rose nearly 2% in early trading Thursday. Shares fell 5.5% Tuesday after the injunction and didn't trade on Wednesday due to the Fourth of July holiday in the U.S.

State-owned chip maker Fujian Jinhua Integrated Circuit Co. and its Taiwanese partner, United Microelectronics Corp., accused Micron in January in China of making products that violate their separate patents. That came a month after the U.S. company filed a lawsuit in California alleging Jinhua and UMC stole Micron's trade secrets at its Taiwan plant. Jinhua has denied the allegations. On Thursday, Micron said Fujian and United Microelectronics filed the lawsuits in "retaliation."

Micron also said the patents are invalid and that its products don't infringe on them.

"The central government of China has often stated that the rights of foreign companies are fairly and equally protected in China," the company said in a statement. "Micron believes the ruling issued by the Fuzhou Court in Fujian Province is inconsistent with this proclaimed policy."

Write to Austen Hufford at [e-mail]


(END) Dow Jones Newswires

July 05, 2018 10:03 ET (14:03 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.

[Werbe]

HI MICK, that was my fathers name lol! Check out $MVES tight share structure!! 2.3 million FLOAT!!! NEAR 52 WEEK LOW!!!!

Share Structure Information (10-19-18)

Outstanding: 109,062,498

Restricted: 106,673,950

Float: 2,388,566

52-Wk Range
0.02 - 2.23


FT LAUDERDALE, Fla., Oct. 29, 2018 (GLOBE NEWSWIRE) -- The Movie Studio, Inc. (OTC PINK: MVES) proudly announces that it will be exhibiting at the 2018 American Film Market in association with Cinema Arts Entertainment. The Company intends to present and solicit release of The Movie Studio's catalog of feature films for worldwide distribution and licensing.

The Movie Studio will be occupying Premier Suite 832# at The American Film Market with Cinema Arts/Artedis and will meet with domestic and international film distributors, buyers and sellers. The Movie Studio intends to secure additional distribution agreements, licensing of current motion picture titles, pre-sales and negative pick-up arrangements as well as the acquisition of additional film libraries and assets for its launch of the Company’s Video on Demand (VOD) and Over the Top (OTT) digital media distribution platform.

About The American Film Market

The American Film Market is the world’s largest motion picture business event. Over 7,000 industry leaders converge in Santa Monica, California for eight days of deal-making, screenings, conferences, networking and parties. Participants come from more than 80 countries and include acquisition and development executives, agents, attorneys, directors, distributors, festival directors, financiers, film commissioners, producers, writers, the world’s press and all those who provide services to the motion picture industry.

Unlike a film festival, the AFM is a marketplace with over 200,000 square feet of exhibition and office space where production and distribution deals are closed. More than US$1 billion in deals will be sealed on both completed films and those in every stage of development and production (negative pick-up).

With 7,000 attendees, 500 screenings, 400 exhibiting distributors, and the industry’s largest Conference series, AFM is the pivotal destination for independent filmmakers and business people from all over the world.

[imgoingfishing1]

SHMN ANNOUNCES SHARES BUYBACK PROGRAM

Chino Hills, 02/26/2019 / 16:31, CET/CEST - EQS Newswire - Sohm, Inc.

CHINO HILLS, CA / ACCESSWIRE / February 26, 2019 / SOHM, Inc. (OTC PINK: SHMN), a generic Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announced today that its Board of Directors has formally approved the initiation of a common stock share buyback program.
SOHM remains focused on continuing efforts to revitalize its business operations, while simultaneously seeking to ensure that the current and potential shareholders remain apprised of ongoing initiatives - all of which will help to ensure our ongoing commitment to maximizing shareholder value.
Accordingly, Mr. Baron Night, President and CEO notes that "we acknowledge that SOHM's current cap structure is not optimal. Instead of a reverse split, we would rather begin taking concrete steps to reduce the company's current outstanding shares while ensuring that our investors do not see their holdings reduced. To that end, the Board of Directors has agreed to engage in a public market based common stock share buyback program."
The buyback program as currently planned will take place between March 1, 2019 and February 28, 2021, with an initial target of 10% of the current outstanding shares of SOHM, Inc. common stock (approximately 154,000,000 shares), with not less than 50% to be retired. Pursuant to the safe harbor provisions of Rule 10b-18, these shares will be acquired by SOHM on the public market, and will be subject to the manner of purchase, timing, price, and volume restrictions specified therein.
SOHM's plan to repurchase these shares is subject to change at any time upon adequate public notice, with the number of shares and definitive timeline to be decided by market conditions and the company's financial status. Any changes to this plan will be noticed via press release and/or filing with OTC Public Markets.

https://www.otcmarkets.com/stock/SHMN/news/EQS-News-SOHM-INC-ANNOUNCES-SHARES-BUYBACK-PROGRAM?id=219521

[$Pistol Pete$]

$BPMX Daily Chart

[imgoingfishing1]

INQD Charts


50/100 MDA




50/200 MDA